A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

Part of paid clinical trials in Andover, Massachusetts.

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT07675811
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Allergic Conjunctivitis

Eligibility Criteria

Sex
ALL
Age
8 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • REGN-2Cat — DRUG
    Administered per the protocol
  • Freneslerbart — DRUG
    Administered per the protocol
  • Mevonlerbart — DRUG
    Administered per the protocol
  • Placebo — DRUG
    Administered per the protocol

Study Details

This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat". These medicines are also known as the "study drugs". The aim of the study is to see what side effects freneslerbart, mevonlerbart, and REGN-2Cat may have and if they help reduce eye allergy symptoms caused by cat hair/dander compared with a placebo. The study is looking at several other research questions, including: * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) * How long the study drug effect lasts

Key Dates

First listed
Jun 30, 2026
Start date
Jul 31, 2026
Status verified
Aug 2026
Primary completion
May 31, 2029
Completion
Sep 20, 2029

Study Design

Enrollment
570 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: REGN-2Cat
    Part A and B
  • Experimental: Freneslerbart
    Part A and B
  • Experimental: Mevonlerbart
    Part A
  • Placebo Comparator: Matching placebo
    Part A and B

Primary Outcome Measure

Ocular itch score in participants receiving REGN-2Cat as compared to placebo [ Time Frame: At day 8, post-Conjunctival Allergen Challenge (CAC) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Andover Eye AssociatesAndoverMassachusetts01810-

Find similar trials in Andover, MA

By research site
Andover Eye Associates· Andover, MA

Related Studies